31 March 2023
EMA/PDCO/108345/2023
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 21-24 February 2023

Chair: Brian Aylward – Vice-Chair: Sylvie Benchetrit

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) pandemic, and the associated EMA Business Continuity Plan (BCP), the meeting was held in-person with some members connected remotely (hybrid setting).

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda for 21-24 February 2023 meeting was adopted with amendments.

1.3. Adoption of the minutes

The minutes for 17-20 January 2023 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Pudexacianinium chloride - EMEA-003099-PIP01-21

Astellas Pharma Europe BV; Visualisation of ureter

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism / Diagnostic / Oncology / Gastroenterology-Hepatology / Uro-nephrology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from birth to less than 18 years of age, in the condition of visualisation of ureter was adopted. The PDCO granted a deferral for the completion of this PIP.

2.1.2. Cilgavimab (AZD1061) / tixagevimab (AZD8895) - EMEA-003079-PIP01-22

AstraZeneca AB; Treatment of coronavirus disease 2019 (COVID-19) / Prevention of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a PIP the fixed-dose combination product cilgavimab (AZD1061) / tixagevimab (AZD8895) for all subsets of the paediatric population (0 to 18 years of age) in the conditions prevention of COVID-19 and treatment of COVID-19. The PIP contains one clinical study covering pre-exposure prophylaxis, treatment of mild to moderate COVID-19 in children at high risk for developing severe disease, and treatment of severe COVID-19, one modelling and simulation study, and one extrapolation study.

2.1.3. Vilobelimab - EMEA-003080-PIP03-22

InflaRx GmbH; Treatment of severe coronavirus disease 2019 (COVID-19)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on previous discussions and the applicant's responses, the PDCO agreed on a positive opinion for vilobelimab for the treatment of coronavirus disease 2019 (COVID-19). The PIP contains one clinical study, one modelling and simulation study, and one extrapolation study.

2.1.4. Zilovertamab vedotin - Orphan - EMEA-003257-PIP01-22

Merck Sharp & Dohme (Europe) Inc.; Treatment of malignant neoplasms of haematopoietic and lymphoid tissue / Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic, and lymphoid tissue)

Day 120 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, positive opinion for the PIP for the proposed medicine zilovertamab vedotin for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic, and lymphoid tissue) and treatment of malignant neoplasms of haematopoietic and lymphoid tissue was adopted. The PDCO granted a deferral for the completion of this PIP.

2.1.5. Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 - Orphan - EMEA-003232-PIP01-22

Inozyme Pharma Ireland Limited; Treatment of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) deficiency

Day 120 opinion

Other / Endocrinology-Gynaecology-Fertility-Metabolism / Cardiovascular Diseases

Summary of Committee discussion:

The PDCO discussed at Day 120, during the February 2023 plenary meeting, an application for a paediatric investigation plan with a deferral for recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 for treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency.
The Committee confirmed all conclusions reached at Day 90 and took into consideration further information provided by the applicant between Day 90 and Day 120.
The PDCO adopted a positive opinion on a paediatric investigation plan with a deferral for children and adolescents from birth to less than 18 years of age.

2.1.6. ABNCoV2 (AV2-cVLP-RBD SARS-CoV-2) - EMEA-003184-PIP01-22

Bavarian Nordic A/S; Prevention of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Vaccines / Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a PIP for AV2-cVLP-RBD SARS-CoV-2 (ABNCoV2) for all subsets of the paediatric population (0 to 18 years of age) in the condition of prevention of COVID-19.
The PIP contains two clinical studies on the use of the vaccine in booster in children from 6 months to less than 18 years of age, and one clinical study for a primary vaccination series in children from birth to less than 18 years of age.

2.1.7. Efzofitimod - EMEA-003352-PIP01-22

FGK Representative Service GmbH; Treatment of pulmonary sarcoidosis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of pulmonary sarcoidosis on the ground of lack of significant therapeutic benefit as clinical trials are not feasible.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.8. Utreloxastat - EMEA-003369-PIP01-22

PTC Therapeutics International; Treatment of amyotrophic lateral sclerosis

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for utreloxastat for all subsets of the paediatric population (birth to less than 18 years of age) in the condition of treatment of amyotrophic lateral sclerosis based on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible. Nevertheless, the Committee encouraged the applicant to consider generating data in paediatrics as well, e.g. by allowing recruitment of any eligible paediatric patients in the adult development programme.

2.1.9. (3S)-3-(5-{4-[(1-{4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2yl)piperidine-2,6-dione - EMEA-003358-PIP01-22

Pfizer Europe MA EEIG; Treatment of breast malignant neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the February 2023 plenary meeting, a request for a product-specific waiver for (3S)-3-(5-{4-[(1-{4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-1-oxo-1,3-dihydro-2H-isoindol-2yl)piperidine-2,6-dione for the treatment of breast malignant neoplasms on the grounds that the disease does not occur in paediatric patients.

The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of malignant breast neoplasms" on the grounds that the disease occurs only in adult populations.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Lutetium 177-labelled radiohybrid prostate-specific membrane antigen-10.1 ((177Lu) rhPSMA-10.1 - EMEA-003353-PIP01-22

Blue Earth Therapeutics Ltd; Treatment of prostate cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the February 2023 plenary meeting, a request for a product-specific waiver for lutetium-177 (177Lu) rhPSMA 10.1 for the treatment of prostate cancer on the grounds that the disease does not occur in paediatric patients.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of prostate cancer" on the grounds that the disease occurs only in adult populations.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Acoltremon - EMEA-003351-PIP01-22

Aerie Pharmaceuticals Ireland, Ltd; Treatment of dry eye disease

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

The PDCO confirmed the outcome of Day 30 discussion and based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant´s request for a waiver. The PDCO recommended granting a waiver for acoltremon for all subsets of the paediatric population (from birth to less than 18 years of age) for the

condition of treatment of dry eye disease on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for the paediatric population.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.12. Ciclosporin - EMEA-003366-PIP01-22

Novaliq GmbH; Treatment of dry eye disease (DED)

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for ciclosporin for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of dry eye disease on the grounds of lack of significant therapeutic benefit, as studies in the paediatric population are not feasible.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.13. Meningococcal group Y oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenY-CRM) / meningococcal group W-135 oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenW-CRM) / meningococcal group C oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenC-CRM) / meningococcal group A oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenA-CRM) - EMEA-000032-PIP02-22

GlaxoSmithKline Biologicals Srl; Prevention of meningococcal meningitidis

Day 60 opinion

Vaccines

Summary of Committee discussion:

Based on the assessment of this application the PDCO agreed with the applicant's request for a waiver. PDCO noted that the applicant is considered to be late according to the Paediatric Regulation given clinical trials have been enrolling children (Study V59_78). The PDCO recommended granting a waiver for meningococcal group C oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenC-CRM) / meningococcal group A oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenA-CRM) / meningococcal group W-135 oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenW-CRM) / meningococcal group Y oligosaccharide conjugated to *Corynebacterium diphteriae* CRM197 protein (MenY-CRM) for all subsets of

the paediatric population (birth to 18 years of age) in the condition of meningococcal meningitis.
The waiver applied to the paediatric population from 6 weeks to less than 18 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered; and the paediatric population from birth to less than 6 weeks of age on the grounds that the specific medicinal product is likely to be ineffective.

2.1.14. Doxazosin (mesilate) / finasteride - EMEA-003380-PIP01-22

Midas Pharma GmbH; Treatment of benign prostate hyperplasia

Day 30 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for finasteride / doxazosin (mesylate) for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of benign prostate hyperplasia.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Finasteride / tadalafil - EMEA-003323-PIP01-22

Dr. Pfleger Arzneimittel GmbH; Treatment of benign prostate hyperplasia

Day 30 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for finasteride / tadalafil for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of benign prostate hyperplasia.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1) - EMEA-003344-PIP02-22

Calico Life Sciences LLC; Treatment of amyotrophic lateral sclerosis

Day 30 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee), the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1) for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of amyotrophic lateral sclerosis.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

2.2.1. Beremagene geperpavec - EMEA-C-002472-PIP03-22

Krystal Biotech Netherlands B.V.; Treatment of dystrophic epidermolysis bullosa

Day 60 opinion

Dermatology

Note: Withdrawal request received on 23 February 2023

2.2.2. Alirocumab - EMEA-C-001169-PIP01-11-M05

sanofi-aventis recherche & développement; Treatment of elevated cholesterol

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001169-PIP01-11-M05

The PDCO adopted on 24 February 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0550/2021) of 31 December 2021.

2.2.3. Dasiglucagon - EMEA-C1-002233-PIP01-17-M01

Zealand Pharma a/s; Treatment of hypoglycaemia

Day 60 letter

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0393/2021) of 8 September 2021.
The PDCO finalised this partially completed compliance procedure on 24 February 2023.

2.2.4. Bezlotoxumab - EMEA-C-001645-PIP01-14-M04

Merck Sharp & Dohme (Europe), Inc.; Prevention of recurrence of *Clostridioides difficile* infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO adopted on 24 February 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0135/2022) of 13 April 2022.

2.2.5. Satralizumab - EMEA-C2-001625-PIP01-14-M06

Roche Registration GmbH; Treatment of neuromyelitis optica

Day 60 letter

Neurology

Summary of Committee discussion:

At Day 60 the PDCO discussed Study 7 including the additional evidence provided by the applicant to support study compliance.
The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0477/2020) of 1 December 2020.
The PDCO finalised this partially completed compliance procedure on 24 February 2023.

2.2.6. Methylphenidate hydrochloride - EMEA-C-003189-PIP01-22-M01

Laboratorios Lesvi S.L.; Treatment of attention-deficit hyperactivity disorder

Day 7 opinion

Psychiatry

The PDCO adopted the opinion by written procedure on 2 February 2023

2.2.7. Sirolimus - EMEA-C1-003168-PIP01-21

Desitin Arzneimittel GmbH; Treatment of tuberous sclerosis

Day 30 letter

Dermatology

Summary of Committee discussion:

The PDCO discussed the completed study and considered that these are compliant with the latest Agency's Decision (P/0480/2022) of 2 December 2022.
The PDCO finalised this partially completed compliance procedure on 24 February 2023.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Remimazolam (besylate) - EMEA-001880-PIP02-19-M04

PAION Deutschland GmbH; General anaesthesia / Sedation

Day 60 opinion

Anaesthesiology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that proposed changes to the dose for the non-clinical studies, the delay in timelines for the completion of studies 5 and 6 and the clarifications in terms of time of assessment of the endpoints for the clinical studies 6, 7 and 8 could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0427/2021 of 29 October 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. Sotatercept - Orphan - EMEA-002756-PIP01-19-M02

Merck Sharp & Dohme B.V.; Treatment of pulmonary arterial hypertension

Day 60 opinion

Cardiovascular Diseases

Note: Withdrawal request received on 6 February 2023

2.3.3. Delgocitinib - EMEA-002329-PIP02-20-M02

LEO Pharma A/S; Treatment of chronic hand eczema

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0098/2022 of 11 March 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Lebrikizumab - EMEA-002536-PIP01-18-M03

Eli Lilly and Company Limited; Treatment of atopic dermatitis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The main changes pertained to the dose and frequency of administration in Study AD13 based on data from studies in adults and adolescents and the results of extrapolation, modelling and simulation Study 1 (study 7 of the PIP).
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0286/2021 of 11 August 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Remibrutinib - EMEA-002582-PIP01-19-M02

Novartis Europharm Limited; Treatment of chronic spontaneous urticaria

Day 60 opinion

Dermatology

Summary of Committee discussion:

In the written response the applicant provided clarification regarding the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0170/2022 of 13 May 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Denosumab - EMEA-000145-PIP02-12-M05

Amgen Europe B.V.; Treatment of osteoporosis

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0213/2021 of 21 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Glucagon analogue linked to a human immunoglobulin Fc fragment - Orphan - EMEA-003170-PIP01-21-M01

Hanmi Pharm. Co., Ltd.; Treatment of congenital hyperinsulinism

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, and additional feedback received after Day 30 discussion, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0468/2022 of 18 November 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Osilodrostat - Orphan - EMEA-000315-PIP02-15-M03

Recordati Rare Diseases SARL; Treatment of adrenal cortical hyperfunction

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0252/2018 of 15 August 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Obeticholic Acid - Orphan - EMEA-001304-PIP02-13-M06

Advanz Pharma Limited; Treatment of biliary atresia / Treatment of primary biliary cirrhosis

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and the discussion in an oral explanation meeting with the

applicant, the PDCO considered that some of the proposed changes could be accepted. The main changes pertained to a request for deletion of Study 5 and updates to the study design of Study 9. Deletion of Study 5 was considered acceptable, however the proposed changes to Study 9 were not acceptable at this stage.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0041/2021 of 27 January 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Andexanet alfa - EMEA-001902-PIP01-15-M07

AstraZeneca AB; Treatment of factor Xa inhibitor associated haemorrhage / Prevention of factor Xa inhibitor associated haemorrhage

Day 60 opinion

Haematology-Hemostaseology

Note: Withdrawal request received on 3 February 2023

2.3.11. Fitusiran - Orphan - EMEA-001855-PIP01-15-M04

Genzyme Europe B.V.; Treatment of congenital haemophilia A / Treatment of congenital haemophilia B

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that only the proposed changes in study timelines could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency´s latest decision (P/0302/2020 of 12 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Filgotinib - EMEA-001619-PIP04-17-M02

Galapagos NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0371/2018 of 6 December 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Tofacitinib - EMEA-000576-PIP01-09-M14

Pfizer Europe MA EEIG; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to the timelines of Studies 7, 8, 10, 11 and 13 could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0227/2020 of 17 June 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Lamivudine / dolutegravir - EMEA-001940-PIP01-16-M05

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and considering the additional information received by the applicant, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0391/2022 of 9 September 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Oritavancin (diphosphate) - EMEA-001270-PIP01-12-M06

Menarini International Operations Luxembourg S.A.; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0236/2022 of 8 July 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Tedizolid phosphate - EMEA-001379-PIP01-12-M07

Merck Sharp & Dohme (Europe), Inc.; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO noted the clarifications provided by the applicant.

Based on the review of the rationale submitted by the applicant to modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0050/2022 of 24 February 2022).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Eculizumab - Orphan - EMEA-000876-PIP03-14-M06

Alexion Europe SAS; Treatment of neuromyelitis optica spectrum disorders

Day 60 opinion

Neurology

Summary of Committee discussion:

In the written response the applicant provided clarification regarding the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes cannot be accepted.
The Committee extended the product-specific waiver of its own motion to cover all subsets of the paediatric population on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO therefore adopted an opinion on the refusal of a modification of the agreed PIP as set in the Agency's latest decision (P/0514/2020 issued on 22 December 2020) and granted a product-specific waiver on its own motion.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Rimegepant - EMEA-002812-PIP02-20-M02

Biohaven Pharmaceutical Ireland DAC; Treatment of migraine headaches

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0299/2022 of 10 August 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Satralizumab - Orphan - EMEA-001625-PIP02-21-M01

Roche Registration GmbH; Treatment of myasthenia gravis

Day 60 opinion

Neurology

Summary of Committee discussion:

In the written response the applicant provided clarification regarding the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0532/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Acalabrutinib - Orphan - EMEA-001796-PIP03-16-M03

Acerta Pharma, BV; Treatment of mature B cell neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The waiver was extended to the age subset from 1 year to less than 18 years of age based on the grounds that the specific medicinal product is likely to be ineffective.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0408/2021 of 8 October 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Carfilzomib - Orphan - EMEA-001806-PIP04-19-M01

Amgen Europe BV; Treatment of acute lymphoblastic leukaemia

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0016/2021 of 27 January 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Selpercatinib - EMEA-002544-PIP01-18-M02

Eli Lilly and Company; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0398/2021 of 30 September 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Temozolomide - EMEA-002634-PIP01-19-M02

Accord Healthcare S.L.U.; Treatment of malignant glioma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes on the timelines accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0418/2021 of 29 October 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.24. Botaretigene sparoparvovec - Orphan - EMEA-002827-PIP01-20-M01

Janssen-Cilag International NV; Treatment of retinitis pigmentosa

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed

paediatric investigation plan, the PDCO considered that some, but not all of the proposed changes could be accepted.
Having reviewed the conclusions reached at Day 30 as well as the additional information received since then, the concern remains that the dataset generated by Studies 4 and 5 may not be appropriate for licensing in paediatric patients. Due to the very small sample size and the additional variabilities to be introduced by the modification proposal the study results are likely to become inconclusive and/or uninterpretable for children. These studies shall, therefore, remain unchanged in the PIP.
The PDCO therefore adopted a partially favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0125/2021 of 17 March 2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.25. Patiromer sorbitex calcium - EMEA-001720-PIP01-14-M03

Vifor Fresenius Medical Care Renal Pharma France; Treatment of hyperkalaemia

Day 60 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The main changes pertained to update of elements of Studies 2 and 3, deletion of the extrapolation study and replacement of this with a modelling and simulation study.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0367/2021 of 8 September 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.26. Zilucoplan - Orphan - EMEA-002747-PIP01-20-M01

UCB Pharma SA; Treatment of myasthenia gravis

Day 60 opinion

Other / Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0143/2021 of 14 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.27. Defatted powder of peanuts - EMEA-001734-PIP01-14-M06

Aimmune Therapeutics Inc; Treatment of peanut allergy

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0132/2021 of 14 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.28. Ravulizumab (ALXN1210) - EMEA-001943-PIP02-20-M02

Alexion Europe SAS; Treatment of patients with haematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)

Day 60 opinion

Uro-nephrology / Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0189/2022 of 10 June 2022).

2.3.29. Gadopiclenol - EMEA-001949-PIP01-16-M05

Guerbet; Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

Day 30 opinion

Diagnostic

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0152/2021 of 16 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.30. Gadopiclenol - EMEA-001949-PIP02-18-M03

Guerbet; Detection and visualization of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes

Day 30 opinion

Diagnostic

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0267/2022 of 4 August 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

2.4.1. Fordadistrogene movaparvovec - Orphan - EMEA-002741-PIP01-20-M01

Pfizer Europe MA EEIG; Treatment of Duchenne muscular dystrophy

Day 30 opinion

Neurology

The PDCO adopted the opinion via written procedure on 17 February 2023

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Dostarlimab - EMEA-C1-002463-PIP01-18-M01

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies)

Day 30 letter

Oncology

2.7.2. Maralixibat chloride - EMEA-C2-001475-PIP03-17-M03

Mirum Pharmaceuticals; Treatment of progressive familial intrahepatic cholestasis

Day 30 letter

Gastroenterology-Hepatology

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. EMEA-002612-PIP02-22

Treatment of sickle cell disease

Day 90 discussion

Haematology-Hemostaseology

3.1.2. Itolizumab - Orphan - EMEA-003208-PIP02-22

Biocon Pharma Malta-I Limited; Treatment of acute graft versus host disease

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.3. Albaconazole - EMEA-003279-PIP01-22

Treatment of acute vulvovaginal candidiasis

Day 90 discussion

Infectious Diseases

3.1.4. Opelconazole - EMEA-003249-PIP01-22

Treatment of bronchopulmonary aspergillosis / Treatment of invasive aspergillosis with indication limited to bronchopulmonary aspergillosis

Day 90 discussion

Infectious Diseases

3.1.5. A 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting fused in sarcoma (FUS) pre-mRNA - EMEA-003024-PIP01-21

Treatment of amyotrophic lateral sclerosis (ALS) patients with fused in sarcoma (FUS) mutations (FUS-ALS) >=12 years of age

Day 90 discussion

Neurology

3.1.6. Ocrelizumab - EMEA-000310-PIP05-22

Treatment of multiple sclerosis

Day 90 discussion

Neurology

3.1.7. Pembrolizumab / favezelimab - EMEA-003104-PIP02-22

Treatment of Hodgkin lymphoma

Day 90 discussion

Oncology

3.1.8. Pembrolizumab / vibostolimab - EMEA-003063-PIP02-22

Treatment of Hodgkin lymphoma

Day 90 discussion

Oncology

3.1.9. Aticaprant - EMEA-003251-PIP01-22

Treatment of major depressive disorder

Day 90 discussion

Psychiatry

3.1.10. Atrasentan - Orphan - EMEA-001666-PIP02-21

Chinook Therapeutics, Inc.; Treatment of IgA nephropathy / Treatment of primary IgA nephropathy

Day 90 discussion

Uro-nephrology

3.1.11. Nizaracianine - EMEA-003367-PIP01-22

Enhancement of the ureters during surgery

Day 60 discussion

Diagnostic

3.1.12. Venglustat - Orphan - EMEA-001716-PIP07-22

Genzyme Europe B.V.; Treatment of Gaucher disease

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.13. Pyridoxal 5'-phosphate monohydrate - Orphan - EMEA-002404-PIP02-22

Medicure Pharma Europe Limited; Treatment of pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Neurology

3.1.14. Govorestat - Orphan - EMEA-003365-PIP01-22

Applied Therapeutics, Inc; Treatment of galactosaemia

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Ophthalmology / Neurology

3.1.15. Fazirsiran - Orphan - EMEA-003355-PIP01-22

Takeda Pharma A/S; Treatment of alpha-1 antitrypsin deficiency-associated liver disease

Day 60 discussion

Gastroenterology-Hepatology

3.1.16. Inhibitor of receptor-interacting protein kinase 1 - EMEA-003356-PIP01-22

Treatment of ulcerative colitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.17. Ruzotolimod - EMEA-003363-PIP01-22

Treatment of chronic hepatitis B

Day 60 discussion

Infectious Diseases

3.1.18. Xalnesiran - EMEA-003362-PIP01-22

Treatment of chronic hepatitis B

Day 60 discussion

Infectious Diseases

3.1.19. Tozorakimab - EMEA-003360-PIP01-22

Treatment of acute respiratory failure

Day 60 discussion

Infectious Diseases / Pneumology - Allergology

3.1.20. Clonidine - EMEA-003198-PIP02-22

Treatment of attention deficit hyperactivity disorder

Day 60 discussion

Neurology

3.1.21. EMEA-003271-PIP02-22

Treatment of primary generalised tonic-clonic seizures

Day 60 discussion

Neurology

3.1.22. Naxitamab - EMEA-002346-PIP02-22

Treatment of osteosarcoma

Day 60 discussion

Oncology

3.1.23. Nemvaleukin alfa - EMEA-003357-PIP01-22

Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue) / Treatment of malignant neoplasms of the lymphoid tissue / Treatment of malignant neoplasms of the central nervous system

Day 60 discussion

Oncology

3.1.24. Tamibarotene - Orphan - EMEA-003329-PIP02-22

Syros Pharmaceutical (Ireland) Limited; Treatment of RARA-positive patients with myelodysplatic syndromes (MDS) / Treatment of RARA-positive patients with acute myeloid leukaemia (AML)

Day 60 discussion

Oncology

3.1.25. Trotabresib - EMEA-003361-PIP01-22

Treatment of malignant neoplasms of the central nervous system

Day 60 discussion

Oncology

3.1.26. Pabinafusp alfa - Orphan - EMEA-003033-PIP02-22

JCR Pharmaceuticals Co., Ltd.; Treatment of mucopolysaccharidosis II (Hunter´s syndrome)

Day 60 discussion

Other

3.1.27. Cannabidiol - Orphan - EMEA-003176-PIP02-22

Zynerba Pharmaceuticals Inc; Treatment of Fragile X syndrome (FXS)

Day 60 discussion

Psychiatry

3.1.28. Inaxaplin - Orphan - EMEA-003368-PIP01-22

Vertex Pharmaceuticals (Ireland) Limited; Treatment of APOL1-mediated kidney disease

Day 60 discussion

Uro-nephrology

3.1.29. Meningococcal group Y oligosaccharides conjugated to *Corynebacterium diphtheriae* CRM197 protein / meningococcal group W-135 oligosaccharides conjugated to *Corynebacterium diphtheriae* CRM197 protein / meningococcal group C oligosaccharides conjugated to *Corynebacterium diphtheriae* CRM197 protein / meningococcal group A oligosaccharides conjugated to *Corynebacterium diphtheriae* CRM197 protein / outer membrane vesicles (OMV) from *N. meningitidis* / recombinant *Neisseria meningitidis* group B fHbp 2-3-1.13NB fusion protein / recombinant *Neisseria meningitis* group B Protein 961c / recombinant *Neisseria meningitis* group B Protein 287-953 / recombinant *Neisseria meningitis* group B Protein 936-741 - EMEA-003359-PIP01-22

Prevention of meningococcal disease

Day 60 discussion

Vaccines

3.1.30. Ezetimibe / atorvastatin - EMEA-003373-PIP01-22

Treatment of homozygous familial hypercholesterolaemia (HoFH) / hypercholesterolaemia

Day 30 discussion

Cardiovascular Diseases

3.1.31. Indapamide / ramipril - EMEA-003372-PIP01-22

Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.1.32. Upadacitinib - EMEA-001741-PIP08-22

Treatment of hidradenitis suppurativa

Day 30 discussion

Dermatology

3.1.33. *Escherichia coli* expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase and L-amino acid deaminase - EMEA-003381-PIP01-22

Treatment of hyperphenylalaninemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.34. Leuprorelin - EMEA-003354-PIP01-22

Treatment of central (gonadotropin-dependent) precocious puberty

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.35. Cemdisiran - Orphan - EMEA-003237-PIP02-22

Regeneron Ireland DAC; Treatment of paroxysmal nocturnal haemoglobinuria

Day 30 discussion

Haematology-Hemostaseology

3.1.36. Pozelimab - EMEA-003238-PIP02-22

Treatment of paroxysmal nocturnal haemoglobinuria

Day 30 discussion

Haematology-Hemostaseology

3.1.37. Axatilimab - EMEA-003385-PIP01-22

Treatment of chronic graft-versus-host-disease

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.38. Nipocalimab - Orphan - EMEA-002559-PIP07-22

Janssen-Cilag International NV; Treatment of Sjögren's syndrome

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.39. Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963) - Orphan - EMEA-003374-PIP01-22

Prevail Therapeutics, a Wholly-Owned Subsidiary of Eli Lilly and Company; Treatment of frontotemporal dementia

Day 30 discussion

Neurology

3.1.40. Inebilizumab - EMEA-001911-PIP02-22

Treatment of generalised myasthenia gravis

Day 30 discussion

Neurology

3.1.41. EMEA-003364-PIP02-22

Treatment of non-small cell lung cancer

Day 30 discussion

Oncology

3.1.42. Cobolimab - EMEA-003273-PIP02-22

Treatment of all conditions included in the category of malignant neoplasms including lymphoma (except lung cancers and hematopoietic malignancies)

Day 30 discussion

Oncology

3.1.43. N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride - Orphan - EMEA-003371-PIP01-22

Relay Therapeutics Inc.; Treatment of cholangiocarcinoma

Day 30 discussion

Oncology

3.1.44. EMEA-003370-PIP01-22

Treatment of recurrent metastatic cancers associated with HPV16 infection including head and neck, anal, cervical, vulvar, vaginal and penile squamous cell carcinomas

Day 30 discussion

Oncology

3.1.45. Pembrolizumab / vibostolimab - EMEA-003063-PIP03-22

Treatment of melanoma

Day 30 discussion

Oncology

3.1.46. A recombinant humanised monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) directed against integrin alpha V beta 8 produced in Chinese hamster ovary (CHO) cells - EMEA-003376-PIP01-22

Treatment of renal cell carcinoma (RCC) / Treatment of head and neck squamous cell carcinoma (HNSCC)

Day 30 discussion

Oncology

3.1.47. Taldefgrobep alfa - EMEA-003386-PIP01-22

Treatment of spinal muscular atrophy

Day 30 discussion

Other

3.1.48. EMEA-003319-PIP04-22

Treatment of borderline personality disorder (BPD)

Day 30 discussion

Psychiatry

3.1.49. *Neisseria meningitidis* serogroup B protein-based active substance / recombinant *Neisseria meningitidis* serogroup B protein 3 / recombinant *Neisseria meningitidis* serogroup B protein 2 / recombinant *Neisseria meningitidis* serogroup B protein 1 / *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein - EMEA-003379-PIP01-22

Prevention of meningococcal disease

Day 30 discussion

Vaccines

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Birch bark extract - EMEA-C-001299-PIP03-17-M01

Amryt Pharmaceuticals DAC; Treatment of epidermolysis bullosa

Day 30 discussion

Dermatology

3.2.2. Eltrombopag - EMEA-C-000170-PIP03-13-M04

Novartis Europharm Limited; Treatment of aplastic anaemia

Day 30 discussion

Haematology-Hemostaseology

3.2.3. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 - EMEA-C1-001160-PIP01-11-M03

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of thrombotic thrombocytopenic purpura

Day 30 discussion

Haematology-Hemostaseology

3.2.4. Givinostat - EMEA-C1-000551-PIP04-21-M01

Italfarmaco S.p.A.; Treatment of Duchenne muscular dystrophy

Day 30 discussion

Neurology

Note: Withdrawal request received on 24 February 2023

3.2.5. Teriflunomide - EMEA-C-001094-PIP01-10-M04

Sanofi Aventis Groupe; Treatment of multiple sclerosis

Day 30 discussion

Neurology

Note: Withdrawal request received on 23 February 2023

3.2.6. Entrectinib - EMEA-C-002096-PIP01-16-M03

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 30 discussion

Oncology

3.2.7. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1 Motifs 13 - EMEA-C1-001160-PIP01-11-M03

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of thrombotic thrombocytopenic purpura

Day 30 discussion

Haematology-Hemostaseology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Tralokinumab - EMEA-001900-PIP02-17-M07

LEO Pharma A/S; Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.3.2. Dasiglucagon - EMEA-002233-PIP01-17-M02

Zealand Pharma A/S; Treatment of hypoglycaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.3. Elosulfase alfa - Orphan - EMEA-000973-PIP01-10-M04

BioMarin International Limited; Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome) in patients of all ages

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Migalastat (hydrochloride) - Orphan - EMEA-001194-PIP01-11-M06

Amicus Therapeutics Europe Limited; Treatment of Fabry disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Romosozumab - EMEA-001075-PIP04-15-M06

UCB Pharma S.A.; Treatment of osteoporosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Tolvaptan - EMEA-001231-PIP02-13-M10

Otsuka Pharmaceutical Netherlands B.V.; Treatment of polycystic kidney disease (PKD)

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

3.3.7. Guselkumab - EMEA-001523-PIP04-19-M02

Janssen-Cilag International NV; Treatment of ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.3.8. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP02-20-M01

Boehringer Ingelheim International GmbH; Treatment of obesity

Day 30 discussion

Gastroenterology-Hepatology

3.3.9. Valoctocogene roxaparvovec - Orphan - EMEA-002427-PIP01-18-M02

BioMarin International Limited; Treatment of haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.3.10. Anifrolumab - EMEA-001435-PIP02-16-M02

AstraZeneca AB; Treatment of systemic lupus erythematosus / lupus nephritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.11. Upadacitinib - EMEA-001741-PIP04-17-M04

AbbVie Ltd; Treatment of atopic dermatitis

Day 30 discussion

Immunology-Rheumatology-Transplantation / Dermatology

3.3.12. Gepotidacin - EMEA-002443-PIP01-18-M02

GlaxoSmithKline Trading Services Limited; Treatment of uncomplicated urinary tract infection (uUTI)

Day 30 discussion

Infectious Diseases

3.3.13. Maribavir - Orphan - EMEA-000353-PIP02-16-M03

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of cytomegalovirus (CMV) infection

Day 30 discussion

Infectious Diseases

3.3.14. Efgartigimod alfa - Orphan - EMEA-002597-PIP05-21-M01

argenx BV; Treatment of myasthenia gravis

Day 30 discussion

Neurology

3.3.15. Lasmiditan - EMEA-002166-PIP01-17-M07

Eli Lilly and Company Limited; Treatment of migraine with and without aura

Day 30 discussion

Neurology

3.3.16. Vatiquinone - Orphan - EMEA-001238-PIP03-21-M01

PTC Therapeutics International; Treatment of Friedreich's ataxia

Day 30 discussion

Neurology

3.3.17. Binimetinib - EMEA-001454-PIP03-15-M03

Pierre Fabre Médicament; Treatment of melanoma

Day 30 discussion

Oncology

3.3.18. Encorafenib - EMEA-001588-PIP01-13-M03

Pierre Fabre Médicament; Treatment of melanoma

Day 30 discussion

Oncology

3.3.19. Isatuximab - EMEA-002205-PIP01-17-M04

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Day 30 discussion

Oncology

3.3.20. Repotrectinib - EMEA-002635-PIP02-21-M01

Bristol-Myers Squibb Pharma EEIG; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic neoplasms)

Day 30 discussion

Oncology

3.3.21. Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human α-L-iduronidase (IDUA) gene - Orphan - EMEA-003001-PIP01-21-M01

Orchard Therapeutics (Netherlands) B.V.; Treatment of mucopolysaccharidosis type I, Hurler syndrome

Day 30 discussion

Other

3.3.22. Iptacopan - Orphan - EMEA-002705-PIP01-19-M01

Novartis Europharm Limited; Treatment of C3 glomerulopathy

Day 30 discussion

Other

3.3.23. Meloxicam / bupivacaine - EMEA-002246-PIP01-17-M03

Heron Therapeutics B.V.; Treatment of acute postoperative pain

Day 30 discussion

Pain

3.3.24. Benralizumab - EMEA-001214-PIP09-21-M01

AstraZeneca AB; Treatment of eosinophilic granulomatosis with polyangiitis (EGPA)

Day 30 discussion

Pneumology - Allergology

3.3.25. Sodium chloride / idrevloride - Orphan - EMEA-002935-PIP01-20-M03

Parion Sciences, Inc.; Treatment of primary ciliary dyskinesia (PCD)

Day 30 discussion

Pneumology - Allergology

3.3.26. Finerenone - EMEA-001623-PIP01-14-M06

Bayer AG; Treatment of chronic kidney disease

Day 30 discussion

Uro-nephrology

3.3.27. Sparsentan - Orphan - EMEA-001984-PIP02-20-M01

Vifor (International) AG; Treatment of focal segmental glomerular sclerosis

Day 30 discussion

Uro-nephrology

3.3.28. Cholera vaccine, recombinant, live, oral (strain CVD 103-HgR) - EMEA-001490-PIP01-13-M04

Emergent Netherlands B.V.; Treatment of cholera disease caused by *Vibrio cholerae* serogroup O1

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of submissions of applications with start of procedure 27 February 2023 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No item

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

No item

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. N-(3-{6-Amino-5-[2-(N-methylprop-2-enamido)ethoxy]pyrimidin-4-yl}-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide - EMEA-002582-PIP01-19

Novartis Pharma AG; Treatment of chronic spontaneous urticaria

Summary of Committee discussion:

The PDCO is of the view that the proposed indication "treatment of patients with chronic inducible urticaria" does not fall under the scope of the above mentioned Decision as the indication is not considered to be covered by the condition "treatment of chronic spontaneous urticaria" listed in the Agency Decision.

The views of the PDCO are based on the following consideration(s): chronic spontaneous urticaria and chronic inducible urticaria are different clinical entities. Although quite similar they could have different triggers and different clinical manifestations, e.g. duration of symptoms.

While both chronic spontaneous urticaria and chronic inducible urticaria could be covered by the condition "treatment of chronic urticaria", the two clinical entities are not interchangeable.

7.1.2. Human papillomavirus type 6 L1 protein / human papillomavirus type 11 L1 protein / human papillomavirus type 16 L1 protein / human papillomavirus type 18 L1 protein / human papillomavirus type 31 L1 protein / human papillomavirus type 33 L1 protein / human papillomavirus type 45 L1 protein / human papillomavirus type 52 L1 protein / human papillomavirus type 58 L1 protein - EMEA-000654-PIP01-09-M02

Merck Sharp & Dohme (Europe), Inc.; Prevention of infection by human papillomavirus

Summary of Committee discussion:

The PDCO is of the view that the proposed indication "prevention of adult onset recurrent respiratory papillomatosis caused by specific HPV types", falls under the scope of the Decision P/0196/2013, as the indication is considered to be covered by the condition "prevention of infection by human papillomavirus" listed in the Agency Decision.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

None

9.1.2. Vote by Proxy

None

9.1.3. Strategic Review and Learning Meeting (SRLM)

No item

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of PIP-related CHMP procedures starting in January 2023, was presented to the PDCO members.

Feedback on the ongoing CHMP procedures was provided to the Committee by the nominated PDCO experts.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The Vice-Chair of the Non-clinical Working Party (NcWP) identified the products which will require NcWP evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward (*ad interim*)

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP)/Healthcare Professionals Working Party (HCPWP)

Summary of Committee discussion:

The draft Agenda of PCWP/HCPWP joint meeting 3 March 2023 and Meeting summary of PCWP/HCPWP annual meeting with all eligible organisations 15 November 2022 were presented for information.

9.3.4. Committee representatives at SAWP: re-nomination composition

Summary of Committee discussion:

The following members were appointed:

- PDCO SAWP member: Dina Apele-Freimane
- PDCO SAWP alternate: Sara Galluzzo

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.5. Cooperation with International Regulators

9.5.1. Paediatric Cluster Teleconference

Summary of Committee discussion:

The 16 February 2023 agenda and minutes of the cluster were shared with the PDCO members for information.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No Item

9.8. Planning and reporting

9.8.1. EMA Business Pipeline activity and Horizon scanning

No item

9.8.2. New key elements form

Summary of Committee discussion:

The draft document was presented and the Committee was invited to provide comments.

10. Any other business

10.1. Feedback from MRCT conference on 'Aligning Stakeholders to Facilitate Pediatric Access to Medicines: From Product Development through HTA Review'

PDCO members: Sylvie Benchetrit, Siri Wang and Sabine Scherer

Summary of Committee discussion:

The Committee was informed about the MRCT conference, including discussions and outcome conclusions, that took place on 24 and 25 January 2023.

10.2. Oncology European Specialised Expert Community (ESEC) webinar on acute myeloid leukaemia (AML)

Summary of Committee discussion:

EMA highlighted the upcoming webinar organised jointly between the Oncology and Haematology Office and the Paediatric Office on acute myeloid leukaemia which will take place on Friday 17th March 2023 at 2 pm. All interested colleagues can join and register through the EU NTC platform.

The PDCO appointed Maaike van Dartel as representative to present on behalf of the Committee.

10.3. Overview of ITF activities in 2022: Trends and topics in focus

Summary of Committee discussion:

An overview of the interactions that took place in 2022 between the ITF and stakeholders on innovative developments was provided.

10.4. PDCO requirement for modifying allergen PIPs

PDCO member: Yuansheng Sun

Summary of Committee discussion:

The Bundesverband der Pharmazeutischen Industrie (BPI) (German manufacturers' representative) sought more clarification on the legal basis of PDCO requirement to modify allergen PIPs only when recruitment of paediatric subjects in the long-term efficacy trials has been started).

The BPI is encouraged to submit a formal question in writing to the PDCO.

10.5. Real World Evidence update, including DARWIN EU®

EMA gave an update on the year 1 studies conducted via DARWIN EU, the onboarded data partners and potential candidates for year 2 studies. The PDCO was also informed of an ongoing review of the experience with real-world evidence studies gained during the past 1.5 year. In addition, EMA presented a brief summary of the findings of the study 'DARWIN EU® - Drug Utilisation Study of Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use' (EUPAS103381) and 'DARWIN EU – Prevalence of rare blood cancers in Europe' (EUPAS50800).

10.6. Upcoming Innovation Task Force (ITF) meetings

Summary of Committee discussion:

Two ITF cases were presented to the Committee for information.

10.7. Update of activities Oncology European Specialised Expert Community (ESEC)

Summary of Committee discussion:

EMA presented an update of the oncology ESEC activities. An oncology expert can still be nominated for the oncology ESEC by sending an e-mail with the experts' names and a brief description of their expertise to EMA.

Recently, a cardiovascular ESEC has been created: nominations of experts can also be sent to EMA.

10.8. Announcement of upcoming FDA workshop on potential study designs for SGLT2 inhibitors for the treatment of paediatric CKD

Summary of Committee discussion:

Products including sodium glucose transporter type 2 inhibitors (SGLT2i) are being developed to slow the progression of chronic kidney disease (CKD) in adults. However, there are challenges related to developing these products for paediatric patients with CKD (e.g., eligibility criteria, feasible study design, endpoints, etc.).

The Committee was informed that the U.S. FDA is planning a workshop on paediatric CKD drug development around early September 2023 to address these issues and that the FDA invites PDCO/EMA experts (and other regulatory agencies) to participate in the workshop. Several members of the Committee expressed their interest in taking part in such a workshop. They will be contacted directly by the FDA with further details in due course.

10.9. Update on planned interactions between CTCG and PDCO

PDCO member: Brian Aylward

Summary of Committee discussion:

The Chair informed the Committee on planned interactions between CTCG and PDCO relating to topics on joint interest.

11. Breakout sessions

11.1. Paediatric oncology

Summary of Committee discussion:

The group was updated on topics and upcoming meetings related to paediatric oncology.

11.2. Neonatology

Summary of Committee discussion:

Members discussed organisational matters for the planned review of the neonatal guideline.

11.3. HIV

Summary of Committee discussion:

Members further discussed feed-back received from experts on the overall issues relating to acceptability of oral formulation. Some proposal to be discussed in the framework SRLM PDCO meeting under the presidency of Spain were put forward.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 21-24 February 2023 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Chair	Ireland	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Marleen Renard	Member	Belgium	No restrictions applicable to this meeting	
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No participation in final deliberations and voting on:	2.3.25. Patiromer sorbitex calcium - EMEA-001720-PIP01-14-M03
Maria Eleni Avraamidou	Alternate	Cyprus	No interests declared	
Tomas Boran	Member	Czechia	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Louisa Braun Exner	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member (Vice-Chair)	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Adrienn Horváth	Member	Hungary	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Dovile	Member	Lithuania	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Zacharkiene				
Carola de Beaufort	Member	Luxembourg	No restrictions applicable to this meeting	
Olivier Moes	Alternate	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No participation in discussion, final deliberations and voting on:	3.2.2. Sirolimus - EMEA-C1-003168-PIP01-21
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Sara Vennberg	Alternate	Sweden	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No interests declared	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jose Ignacio Malagon	Alternate	Healthcare Professionals'	No restrictions applicable to this	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Calle		Representative	meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Member	Patients' Organisation Representative	No interests declared	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Celine Chu	Expert - via telephone*	France	No interests declared	
André Elferink	Expert - via telephone*	Netherlands	No interests declared	
Maija Tarkkanen	Expert - via telephone*	Finland	No interests declared	
Armin Koch	Expert - via telephone*	Germany	No restrictions applicable to this meeting	
Anja Schiel	Expert - via telephone*	Norway	No interests declared	
Meeting run with support from relevant EMA staff				

*Experts were evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (*section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs*)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (*section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check*)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (*section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP*)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (*section 6 Discussion on the applicability of class waiver*)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (*section 8*)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/